Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 44.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,275 shares of the medical equipment provider’s stock after selling 32,591 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Hologic were worth $1,828,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the company. TrimTabs Asset Management LLC raised its position in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares during the last quarter. Beck Mack & Oliver LLC bought a new position in shares of Hologic during the second quarter valued at $209,000. Notis McConarty Edward bought a new position in shares of Hologic during the second quarter valued at $213,000. Advisor Partners LLC bought a new position in shares of Hologic during the first quarter valued at $201,000. Finally, CAPROCK Group Inc. bought a new position in shares of Hologic during the second quarter valued at $214,000. 94.43% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Hologic, Inc. (NASDAQ HOLX) opened at 38.21 on Thursday. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The firm has a market capitalization of $10.72 billion, a P/E ratio of 14.23 and a beta of 0.90. The firm’s 50-day moving average is $43.08 and its 200-day moving average is $42.88.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 earnings per share. Equities analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current year.
Several research firms recently commented on HOLX. Royal Bank Of Canada decreased their price target on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Canaccord Genuity restated a “buy” rating and issued a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Finally, Needham & Company LLC restated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $48.64.
In related news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the sale, the director now directly owns 23,810 shares of the company’s stock, valued at $955,257.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,551 shares of company stock worth $2,244,458. Insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.